{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:33:02Z","timestamp":1792204382102,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Israel Cancer Research FundIsrael Cancer Research Fund"},{"name":"Lipomedix Pharmaceuticals Ltd."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jconrel.2016.01.039","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T07:31:04Z","timestamp":1453447864000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity"],"prefix":"10.1016","volume":"225","author":[{"given":"Yogita","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Amitay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ohana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Shmeeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gabizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.01.039_bb0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0305-7372(76)80019-9","article-title":"Mitomycin C: a review","volume":"3","author":"Crooke","year":"1976","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0006-2952(86)90559-9","article-title":"The role of mitomycin antibiotics in the chemotherapy of solid tumors","volume":"35","author":"Sartorelli","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0163-7258(97)00088-0","article-title":"The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity","volume":"76","author":"Tomasz","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0020","first-page":"501","article-title":"Mitomycin C: a prototype bioreductive agent","volume":"6","author":"Sartorelli","year":"1993","journal-title":"Oncol. Res."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0025","doi-asserted-by":"crossref","first-page":"19068","DOI":"10.1074\/jbc.M109.040477","article-title":"Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs","volume":"285","author":"Snodgrass","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","article-title":"Mitomycin C: mechanism of action, usefulness and limitations","volume":"1","author":"Verweij","year":"1990","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/ctrv.2000.0202","article-title":"Mitomycin C: a clinical update","volume":"27","author":"Bradner","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0040","first-page":"3","article-title":"The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy","volume":"1","author":"Monden","year":"1998","journal-title":"Int. J. Surg. Investig."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0045","first-page":"4073","article-title":"Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P-glycoprotein and apoptotic factors","volume":"22","author":"Gontero","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/jsre.1998.5481","article-title":"The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines","volume":"80","author":"Lambert","year":"1998","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0060","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/1097-0142(19870815)60:4<756::AID-CNCR2820600408>3.0.CO;2-H","article-title":"Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis","volume":"60","author":"Verweij","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0065","series-title":"Seminars in oncology","first-page":"32","article-title":"New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C","author":"Dorr","year":"1988"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0070","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1073\/pnas.88.24.11460","article-title":"Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy","volume":"88","author":"Papahadjopoulos","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0075","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/1061186021000043061","article-title":"Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects","volume":"10","author":"Gabizon","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0080","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/1078-0432.CCR-05-1547","article-title":"Reduced toxicity and Superior therapeutic activity of a mitomycin C Lipid-Based Prodrug Incorporated in pegylated liposomes","volume":"12","author":"Gabizon","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/10611860701499946","article-title":"Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action","volume":"15","author":"Zalipsky","year":"2007","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0090","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/cam4.491","article-title":"Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients","volume":"4","author":"Golan","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0095","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1021\/jo00296a082","article-title":"Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides","volume":"55","author":"Senter","year":"1990","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0100","article-title":"Pharmacologic studies of a prodrug of mitomycin C in pegylated liposomes (promitil\u00ae): high stability in plasma and rapid thiolytic prodrug activation in tissues","author":"Amitay","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jconrel.2011.11.019","article-title":"Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models","volume":"160","author":"Gabizon","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0110","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1073\/pnas.77.7.4089","article-title":"Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells","volume":"77","author":"Leserman","year":"1980","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0115","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1073\/pnas.88.13.5572","article-title":"Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis","volume":"88","author":"Leamon","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","article-title":"Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes","volume":"86","author":"Symon","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4155\/tde.10.30","article-title":"Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents","volume":"1","author":"Torchilin","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0130","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1158\/1078-0432.CCR-09-3199","article-title":"Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model","volume":"16","author":"Tuscano","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0135","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.addr.2004.02.003","article-title":"Folate receptor-targeted drugs for cancer and inflammatory diseases","volume":"56","author":"Low","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0140","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.addr.2004.01.011","article-title":"Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid\u2013PEG conjugates","volume":"56","author":"Gabizon","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0145","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0150","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/S0021-9258(17)41848-5","article-title":"Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis","volume":"269","author":"Lee","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0155","doi-asserted-by":"crossref","first-page":"13872","DOI":"10.1073\/pnas.0601455103","article-title":"Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging","volume":"103","author":"Yang","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0160","first-page":"1277","article-title":"Folate-targeted drug strategies for the treatment of cancer","volume":"9","author":"Leamon","year":"2008","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0165","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/1535-7163.MCT-05-0543","article-title":"Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors","volume":"5","author":"Shmeeda","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-009-1132-4","article-title":"Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models","volume":"66","author":"Gabizon","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2010.04.028","article-title":"Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells","volume":"146","author":"Shmeeda","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0180","unstructured":"S. Zalipsky, A.A. Gabizon, Conjugate having a cleavable linkage for use in a liposome, US6365179 B1, 2002."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/160967","article-title":"Effects of polyethylene glycol spacer length and ligand density on folate receptor targeting of liposomal doxorubicin In Vitro","author":"Kawano","year":"2011","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0190","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0005-2736(92)90084-Y","article-title":"In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release","volume":"1109","author":"Horowitz","year":"1992","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0195","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.150.3.693","article-title":"Thymic reconstitution of nude F1 mice with one or both parental thymus grafts","volume":"150","author":"Zinkernagel","year":"1979","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0005-2736(94)00235-H","article-title":"Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro","volume":"1233","author":"Lee","year":"1995","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0205","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1126\/science.1310359","article-title":"Potocytosis: sequestration and transport of small molecules by caveolae","volume":"255","author":"Anderson","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-3659(97)00236-8","article-title":"Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells","volume":"53","author":"Wang","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0215","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/bjc.1996.625","article-title":"Targeting of stealth liposomes to erbB-2 (Her\/2) receptor: in vitro and in vivo studies","volume":"74","author":"Goren","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0220","first-page":"6551","article-title":"In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice","volume":"9","author":"Gabizon","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0225","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0230","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tibtech.2008.06.007","article-title":"Does a targeting ligand influence nanoparticle tumor localization or uptake?","volume":"26","author":"Pirollo","year":"2008","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0235","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/1097-0142(20000601)88:11<2512::AID-CNCR12>3.0.CO;2-J","article-title":"Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis","volume":"88","author":"Beaujard","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2016.01.039_bb0240","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/ejso.1999.0927","article-title":"Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis","volume":"26","author":"Cavaliere","year":"2000","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0245","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0022-5347(01)66225-6","article-title":"Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer","volume":"155","author":"Colombo","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.jconrel.2016.01.039_bb0250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","article-title":"Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma","volume":"52","author":"Paroni","year":"2001","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916300359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916300359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T04:52:50Z","timestamp":1654145570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916300359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":50,"alternative-id":["S0168365916300359"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.039","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}